Related Experiment Video
Updated: May 21, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Targeted therapy in Ewing sarcoma
1Division of Pediatric Hematology and Oncology, Department of Pediatrics, University Medical Center Freiburg, 79106 Freiburg, Germany.
Abstract:
Despite marked improvement in the prognosis of patients with nonmetastatic Ewing sarcoma (ES), the outcome for patients with recurrent or metastatic disease remains poor. Insight into key biologic processes in ES could provide new therapeutic targets. The particular biologic feature of ES, the fusion of the EWS gene with a member of the ETS family of genes, is present in >95% of cases. The EWS-ETS chimeric protein leads to aberrant transcription that promotes tumor initiation and propagation via prosurvival and antiapoptotic pathways. Recent research has identified cooperating mutations important for ES tumorigenesis. This paper provides a summary of the latest research in ES and discusses potential novel targets for therapy.
Insights
Despite advances in treating nonmetastatic Ewing sarcoma (ES), outcomes for recurrent or metastatic disease remain poor. This review summarizes recent Ewing sarcoma research, focusing on the EWS-ETS fusion and cooperating mutations as potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Nonmetastatic Ewing sarcoma (ES) prognosis has improved, but outcomes for recurrent or metastatic disease are poor.
- The EWS-ETS fusion gene is a hallmark of over 95% of ES cases, driving tumor growth.
- Understanding ES biology is crucial for developing new therapies.
Purpose of the Study:
- To summarize recent research findings in Ewing sarcoma (ES).
- To identify and discuss novel therapeutic targets for ES.
- To highlight the role of the EWS-ETS fusion protein and cooperating mutations.
Main Methods:
- Literature review of recent studies on Ewing sarcoma.
- Analysis of the molecular biology and genetic alterations in ES.
- Identification of key pathways involved in ES tumorigenesis.
Main Results:
- The EWS-ETS chimeric protein drives aberrant transcription, promoting tumor initiation and survival.
- Cooperating mutations play a significant role in ES development.
- Recent research provides insights into the molecular mechanisms of ES.
Conclusions:
- The EWS-ETS fusion and cooperating mutations are critical for ES pathogenesis.
- Targeting these molecular alterations holds promise for novel ES therapies.
- Further research into ES biology is essential for improving patient outcomes.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

